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wholesale acquisition cost with consideration of contractual dis-
counts and patient co-payment. The primary economic endpoint
was cost per relapse avoided over a 4-year period of treatment.
RESULTS: The ARR varied across the ﬁve DMDs with inter-
feron beta-1a SC injection (Rebif®) showing the highest results
(0.72) and interferon beta-1a IM injection (Avonex®) the lowest
(0.26). Economic results showed signiﬁcant difference in the
cost-effectiveness ratio (CER) among the DMDs, with interferon
beta-1a SC injection (Rebif®) having the most favorable CER
(US$47958/relapse avoided) and interferon beta-1a IM injection
(Avonex®) having the least favorable (US$121,147/relapse
avoided). Interferon beta-1b SC injection (Betaseron®), 
glatiramer acetate SC injection (Copaxone®), and natalizumab
IV injection (Tysabri®) offer intermediate CER results of
US$48,345, US$68,440, and US$93,903 per relapse avoided,
respectively. CONCLUSION: Modeling absolute reduction 
in clinical endpoints provides a methodology for comparing 
clinical trials and demonstrates that the difference in cost-
effectiveness results among the DMDs is signiﬁcant.
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OBJECTIVE: To examine the cost-effectiveness of ropinirole for
the treatment of primary restless legs syndrome (RLS) versus the
alternative off-label therapies of pramipexole and pergolide.
METHODS: A cost-effectiveness analysis was conducted from
the societal perspective using a cohort of 10,000 United States
adults 45 years old and older with moderate-to-severe primary
RLS. A decision tree was used to model cost-effectiveness for a
two-year period following commencement of dopamine agonist
therapy. Outcome probabilities were obtained from a systematic
review of randomized controlled trials and observational studies.
Costs were derived from standard 2005 health care cost refer-
ences. Cost-effectiveness decision models were created for base-
case analyses. One-way and probabilistic sensitivity analyses
were conducted to test the robustness of the ﬁndings. RESULTS:
In terms of changes in the International Restless Legs Syndrome
Study Group Rating Scale (IRLS) score for RLS severity, per-
golide dominates ropinirole given the base-case. Pergolide is 
cost-saving when compared to both ropinirole and pramipexole,
resulting in a saving of $1687 and $556 per one-point improve-
ment in IRLS score. One-way sensitivity analyses indicated that
the IRLS scores for augmentation strongly inﬂuenced the calcu-
lated incremental cost effectiveness ratios (ICERs). Probabilistic
sensitivity analyses revealed variation in the results indicating a
lack of clear dominance. CONCLUSIONS: None of the thera-
pies is clearly dominant in terms of cost per IRLS score change.
Although ropinirole is currently the only U.S. Food and Drug
Administration (FDA) approved medication for the treatment of
RLS, it is not more cost-effective than alternate off-label
dopamine agonists prescribed for RLS.
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OBJECTIVE: To determine the effect of neutralizing antibodies
(NAbs) on the cost-effectiveness of disease-modifying agents
(DMAs) used to treat multiple sclerosis (MS). METHODS: A
cost-effectiveness model was developed using relapse rate and
disability progression endpoints from pivotal phase III trials of
currently approved DMAs for MS (interferon beta [IFNB]-1a IM
[Avonex], IFNB-1a SC [Rebif], IFNB-1b [Betaseron], and glati-
ramer acetate [GA; Copaxone]). The model was created from a
managed care perspective with time horizons of 24 and 48
months. Cost-effectiveness is expressed as a ratio of total uti-
lization costs per percent relative risk reduction for relapses and
disability progression; daily cost-effectiveness is shown as per
percentage point reduction. The incidence of NAbs and their
effect on efﬁcacy was obtained from prescribing information,
open-label extension studies of IFNB products, and a large pop-
ulation study. The model includes the following assumptions:
comparison of similar endpoints across different clinical trials;
constant adverse event rates among products; constant burden
of relapse over time; constant persistence/compliance rates
among products; similar laboratory testing/frequency among
IFNB products. A one-way sensitivity analysis was conducted to
test the robustness of the model to changes in NAb incidence.
RESULTS: At 24 months, the cost-effectiveness for disability
progression was $824 ($1.13/day) for IFNB-1a IM, $1222
($1.67/day) for IFNB-1a SC, $1150 ($1.57/day) for IFNB-1b,
and $2558 ($3.50/day) for GA. After the development of NAbs,
at 48 months cost-effectiveness was $1659 ($1.14/day) for
IFNB-1a IM, $2536 ($1.74/day) for IFNB-1a SC, $2433
($1.67/day) for IFNB-1b, and $5117 ($3.50/day) for GA. Results
were similar for relapse rate. Results of sensitivity analyses 
conﬁrmed the robustness of the model. CONCLUSIONS: NAbs
reduce the cost-effectiveness of IFNB products. IFNB-1a IM
(Avonex) was the most cost-efﬁcacious DMA before (24 months)
and after (48 months) the development of NAbs.
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OBJECTIVES: Using long-term follow-up data from clinical
trials, this analysis assesses the cost-effectiveness of ﬁve treat-
ment strategies in patients diagnosed with relapsing-remitting
multiple sclerosis (RRMS): symptom management alone (SMA)
and symptom management combined with subcutaneous glati-
ramer acetate (SCGA), intramuscular interferon beta-1-a (IM-
IFNb1-a), subcutaneous interferon beta-1-a (SC-IFNb1-a), or
subcutaneous interferon beta-1-b (SC-IFNb1-b). METHODS: A
literature-based Markov model was developed to assess the cost-
effectiveness of ﬁve treatment strategies for managing a hypo-
